Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 17;23(2):977.
doi: 10.3390/ijms23020977.

Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases

Francesco Amati  1   2 , Anna Stainer  1   2 , Marco Mantero  3   4 , Andrea Gramegna  3   4 , Edoardo Simonetta  3   4 , Giulia Suigo  1   2 , Antonio Voza  1   5 , Anoop M Nambiar  6 , Umberto Cariboni  7 , Justin Oldham  8 , Philip L Molyneaux  9 , Paolo Spagnolo  10 , Francesco Blasi  3   4 , Stefano Aliberti  1   2
Affiliations
Review

Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases

Francesco Amati et al. Int J Mol Sci. .

Abstract

Interstitial lung diseases represent a heterogeneous and wide group of diseases in which factors leading to disease initiation and progression are not fully understood. Recent evidence suggests that the lung microbiome might influence the pathogenesis and progression of interstitial lung diseases. In recent years, the utilization of culture-independent methodologies has allowed the identification of complex and dynamic communities of microbes, in patients with interstitial lung diseases. However, the potential mechanisms by which these changes may drive disease pathogenesis and progression are largely unknown. The aim of this review is to discuss the role of the altered lung microbiome in several interstitial lung diseases. Untangling the host-microbiome interaction in the lung and airway of interstitial lung disease patients is a research priority. Thus, lung dysbiosis is a potentially treatable trait across several interstitial lung diseases, and its proper characterization and treatment might be crucial to change the natural history of these diseases and improve outcomes.

Keywords: interstitial lung diseases; microbiome; treatable traits.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest concerning this review.

References

    1. Travis W.D., Costabel U., Hansell D.M., King T.E., Jr., Lynch D.A., Nicholson A.G., Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013;188:733–748. doi: 10.1164/rccm.201308-1483ST. - DOI - PMC - PubMed
    1. Betensley A., Sharif R., Karamichos D. A Systematic Review of the Role of Dysfunctional Wound Healing in the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis. J. Clin. Med. 2016;6:2. doi: 10.3390/jcm6010002. - DOI - PMC - PubMed
    1. Jain M., Rivera S., Monclus E.A., Synenki L., Zirk A., Eisenbart J., Chandel N.S. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 2011;364:1503–1512. doi: 10.1056/NEJMoa1013660. - DOI - PMC - PubMed
    1. Legendre M., Butt A., Borie R., Debray M.P., Bouvry D., Filhol-Blin E., Nathan N. Functional assessment and phenotypic heterogeneity of SFTPA1 and SFTPA2 mutations in interstitial lung diseases and lung cancer. Eur. Respir. J. 2020;56:2002806. doi: 10.1183/13993003.02806-2020. - DOI - PubMed
    1. Yang I.V., Fingerlin T.E., Evans C.M., Schwarz M.I., Schwartz D.A. MUC5B and Idiopathic Pulmonary Fibrosis. Ann. Am. Thorac. Soc. 2015;12((Suppl. S2)):S193–S199. doi: 10.1513/AnnalsATS.201503-110AW. - DOI - PMC - PubMed

MeSH terms